ProCE Banner Activity

Phase III CANDOR Trial of Carfilzomib, Dexamethasone ± Daratumumab in Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
The phase III CANDOR trial demonstrated significant PFS benefit with carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Released: December 16, 2019

Expiration: December 14, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company